NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JAPIC ID: JapicCTI-121907

Registered date:

Z-103 Phase III Clinical Study in patients with Taste Disorder - A placebo-controlled superiority study -

Basic Information

Recruitment status
Health condition(s) or Problem(s) studiedtaste disorders induced by zinc-deficiency
Date of first enrollment01/6/2012
Target sample size260
Countries of recruitment
Study typeINTERVENTIONAL
Intervention(s)Intervention name : Z-103 INN of the intervention : Polaprezinc Dosage And administration of the intervention : Oral administration of one tablet twice a day after meal Control intervention name : placebo Dosage And administration of the control intervention : Oral administration of one tablet twice a day after meal

Outcome(s)

Primary OutcomeFinal overall efficacy evaluation Filter-paper Disk Method
Secondary OutcomeEfficacy evaluation at each evaluation period Filter-paper Disk Method

Key inclusion & exclusion criteria

Age minimum20
Age maximum74
GenderBOTH
Include criteriaPatients diagnosed with the following three types. 1. Zinc-deficient taste disorder 2. Idiopathic taste disorder 3. Drug-induced taste disorder (with some exceptions)
Exclude criteria1. Central nervous system disorder 2. Peripheral neuropathy 3. Intraoral defect and salivary gland disorder 4. Psychiatric disorder 5. Systemic disorders that cause taste disorder

Related Information

Contact

public contact
Name Zeria Pharmaceutical Co., Ltd. R & D Planning
Address 03-5644-7053
Telephone
E-mail
Affiliation
scientific contact
Name
Address
Telephone
E-mail
Affiliation